Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls
Analyst actions highlighted: Argus upgraded Bristol Myers (BMY) to Buy, $75 target, citing margin improvement and raised 2026 guidance. Freedom Broker upgraded McDonald's (MCD) to Buy, $305 target, on softer revenue and comps. Morgan Stanley upgraded Humana (HUM) to Equal Weight, $370 target. Jefferies downgraded Best Buy (BBY) to Hold, $85 target. Others included upgrades/downgrades for several stocks with updated price targets.
How this was made
The 30-second read
Why it matters
Net effect is a sentiment reshuffle across consumer discretionary (BBY, MCD), healthcare (BMY, HUM, ILMN, OBX), industrials/logistics (EXPD, TDG, CECO), and financial/tech (FIS).
Market read
For trading, the actionable element is the immediate re-pricing risk from today’s upgrades/downgrades and target changes, especially where the thesis references demand trends or guidance resets.
What to watch
The article provides no actual earnings numbers, guidance figures, or deal terms beyond qualitative claims, so traders should verify whether the cited 'raised/reduced guidance' is already known and whether the market has already priced the rating changes.
Background
The piece is a multi-stock roundup of analyst rating changes and price-target updates from several firms.
Ticker impact
Argus upgraded Bristol Myers to Buy and raised its 2026 earnings guidance, citing margin improvement and potential M&A interest.
Mild-to-moderate positive drift possible as traders price the upgrade and guidance narrative.
The article provides a clear rating change and a specific thesis (turnaround, margin improvement, raised guidance, AZN M&A interest), but no new company filing or hard datapoint beyond the guidance reference.
Jefferies downgraded Best Buy to Hold, pointing to a July downshift in consumer purchase intentions ahead of a tough 2026 Q3 compare.
Downward bias likely, especially if positioning reacts to the downgrade and the Q3 compare warning.
The thesis is specific (July downshift, hardest compare in Q3), but the catalyst is still an analyst note rather than a new earnings print or filing.
Freedom Broker upgraded McDonald's to Buy while citing softer-than-expected revenue and weaker U.S. comparable sales growth.
Limited upside bias; reaction may depend on whether traders focus more on the upgrade or the weaker sales commentary.
The article mixes an upgrade with negative performance descriptors, and it does not provide new quantitative results beyond the qualitative 'softer than expected' framing.
Morgan Stanley upgraded Humana to Equal Weight, citing improving visibility into Medicare Advantage cost trends.
Moderate positive bias possible as uncertainty premium compresses.
The upgrade is directly tied to a concrete driver (MA cost visibility), but it remains a research-note change without new regulatory or earnings data.
JPMorgan upgraded Expeditors to Neutral, attributing the call to momentum supported by an 'unprecedented restructuring effort' by new management.
Likely stabilization rather than a strong directional move.
The thesis is specific, but the rating is only Neutral and the article lacks new operational metrics.
Bernstein upgraded Elf Beauty to Outperform, arguing the company has a consumer-relevant operating model with rapid innovation and viral product development.
Potential upside bias if traders buy into the operating-model narrative.
The article provides a clear upgrade thesis but no new product/financial datapoint beyond the qualitative model description.
Roth Capital? No. Stifel downgraded TransDigm to Hold, saying the fiscal Q3 report was strong but valuation faces rising risks.
Downward or capped upside bias possible as valuation concerns dominate.
The article explicitly links the downgrade to valuation risk despite a strong Q3 report, which is a meaningful near-term sentiment driver.
Citi downgraded Burlington Stores to Neutral citing valuation near its price target, while Morgan Stanley resumed coverage with Overweight.
Choppy trading possible; direction likely depends on which note gains more traction.
Two different firms issue opposite-leaning calls, and the article does not add new company-specific facts beyond valuation framing.
Market effects
Broad retail, healthcare, and financials sentiment shifts via multiple analyst rating changes, but no single sector-wide regulatory or earnings catalyst is disclosed.
Primarily US-listed names; limited direct regional spillover beyond sentiment in consumer discretionary and healthcare.
M&A speculation is mentioned only as a potential catalyst (AZN interest in BMY), without a confirmed cross-border transaction.
Counterpoint
Analyst upgrades and downgrades can fade quickly if they are not backed by new company disclosures; several notes cite 'priced in' or valuation rather than fresh fundamentals.
Key entities
- companyBristol Myers
Upgraded to Buy by Argus with a $75 target, citing turnaround signs, margin improvement, raised 2026 guidance, and possible M&A interest.
- companyBest Buy
Downgraded to Hold by Jefferies with an $85 target, citing a July downshift in purchase intentions and a tough Q3 compare.
- companyFIS
Downgraded to Neutral by UBS with a $49 target, citing reduced 2026 revenue and profitability guidance.
